The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

US pharma giant Merck & Co opened Tuesday’s trading 10% lower after announcing its annual and fourth quarter financial ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Merck stock fell in premarket trading Tuesday after the company said sales of its blockbuster HPV vaccine, Gardasil, declined ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

The TSX parent reported adjusted earnings per share of 48 cents, topping the Street’s expectation by 4 cents as organic ...

The new confirmation include 5 from Missouri, a state that has lost about 4.3 million poultry over the last 30 days.

But rates of types 31/33/45, 47, and 45 were lower in vaccinated women, which the authors said suggests that the vaccines ...

Meanwhile, Oyo State Coordinator for NPHCDA, Mr. Alasan Babatunde, reported that Nigeria has achieved a 71% vaccination coverage since the HPV vaccine's introduction in ... targets school-aged girls ...

Over the last few quarters, sales of the company’s staple Gardasil vaccine franchise have ... to generate net product revenue between $2.9 billion and $3.1 billion. “2024 marked the most ...